Who is sponsoring NCT02632578?

NCT02632578 is sponsored by University of Melbourne.

What drugs are being tested in NCT02632578?

Interventions in NCT02632578: 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine).

What condition does NCT02632578 study?

NCT02632578 studies Influenza, Human.

Is NCT02632578 still recruiting?

NCT02632578 is currently completed. Last updated 15 December 2015.

Last reviewed 2015-12-15 · How we verify

NCT02632578

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comparison of Immune Responses to the Licensed Trivalent Inactivated Influenza Vaccine in HIV-positive and HIV-negative Subjects

Completed Last updated 15 December 2015

What this trial tests

trial testing 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine) in Influenza, Human in 57 participants. Completed in 1 December 2015.

Timeline

1 February 2015

Primary endpoint
1 June 2015

1 December 2015

Quick facts

Lead sponsor	University of Melbourne
Status	Completed
Study type	OBSERVATIONAL
Enrollment	57
Start date	1 February 2015
Primary completion	1 June 2015
Estimated completion	1 December 2015

Drugs / interventions tested

2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine) — full drug profile →

Conditions studied

Influenza, Human — all drugs for Influenza, Human →

Sponsor

University of Melbourne

Who can join

Adults 18 to 55, any sex, with Influenza, Human. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Anti-influenza antibody responses in plasma with Fc-mediated functions
Time frame: Four weeks after influenza vaccination

Sponsor's own description

The aims of this study are: 1. to investigate if HIV infection alters the antibody responses to influenza and 2. to assess the ability of licensed influenza vaccine to induce functional non-neutralising antibodies in HIV-infected and HIV-uninfected subjects.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem.
Tan HX, Jegaskanda S, Juno JA, Esterbauer R, et al · · 2019 · cited 84× · PMID 30521496 · DOI 10.1172/jci123366
Cross-lineage protection by human antibodies binding the influenza B hemagglutinin.
Liu Y, Tan HX, Koutsakos M, Jegaskanda S, et al · · 2019 · cited 75× · PMID 30659197 · DOI 10.1038/s41467-018-08165-y
HIV-dependent depletion of influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza immunisation.
Wheatley AK, Kristensen AB, Lay WN, Kent SJ. · · 2016 · cited 31× · PMID 27220898 · DOI 10.1038/srep26478

Verify or expand the search:

Other recruiting trials for Influenza, Human

Currently open trials in the same condition.

NCT07204964 — A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above · Phase 2 · active not recruiting
NCT07121192 — A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older · Phase 2 · active not recruiting
NCT05921448 — Vaccine Pandemic Preparedness Through Airway Immunology Characterization · EARLY_PHASE1 · active not recruiting
NCT06573008 — Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications · Phase 3 · recruiting
NCT06622590 — Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine · Phase 1 · active not recruiting

Other University of Melbourne trials

Trials by the same sponsor.

NCT06461429 — PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol] · NA · not yet recruiting
NCT07055542 — Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study · NA · recruiting
NCT06965751 — A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 · Phase 1 · active not recruiting
NCT06972810 — Human Infection Study of H3N2 Influenza in Healthy Adults · NA · active not recruiting
NCT06885151 — A New Website for Australian IVF Patients: 'Evidence-based IVF' · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02632578 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Melbourne
Last refreshed: 15 December 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02632578.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing